Immune Response in the Management of MS

Barry A. Hendin, MD, and Regina Berkovich, MD, PhD, provide an overview of the immune system, focusing on innate vs adaptive immunity, in the management of multiple sclerosis.

Barry A. Hendin, MD, discusses innate and adaptive immunity and BTK inhibitors in the treatment of multiple sclerosis (MS).

Regina Berkovich, MD, PhD, defines inflammation in multiple sclerosis and its role in MS pathogenesis.

Dr Barry A. Hendin reviews the use of high efficacy therapy in MS.

Regina Berkovich, MD, PhD, shares her approach to selecting high-efficacy therapies in clinical practice for patients with multiple sclerosis.

Expert neurologists discuss factors guiding their choice of high-efficacy therapy in multiple sclerosis.

Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review clinical implications of real-world data on the use of cladribine and other DMTs in patients with relapsing MS that were presented at ACTRIMS 2022.

Drs Barry A. Hendin and Regina Berkovich comment on the management and treatment of chronic smoldering inflammation with high efficacy therapies.

Barry A. Hendin, MD, reviews guidance on COVID-19 vaccines for patients with MS, including highlights from the AAN position statement.

Dr Regina Berkovich evaluates the use of mRNA COVID-19 vaccines in patients treated with high efficacy disease-modifying therapies for MS.

Clinical implications from VELOCE, a phase 3b study examining the effect of ocrelizumab on immune responses in patients with relapsing MS.

Expert neurologists comment on the impact of COVID-19 on telemedicine and MS treatment selection.

Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review potential use of BTK inhibitors in the treatment of MS.

Barry A. Hendin, MD; Regina Berkovich, MD, PhD; and Ahmed Z. Obeidat, MD, PhD, explore the role of biomarkers, precision medicine, and repair mechanisms to improve treatment of MS going forward.

Expert neurologists emphasize the importance of conversations around patient lifestyle, mental health, and comorbid conditions as keys to improve care for MS.